Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of McKesson Corporation. A complete text table follows the diagram.
Enormous drug-distribution volume runs on razor-thin margins, while oncology services and prescription technology add faster-growing, higher-value layers
Swipe to explore
All segment and income-statement values are directly reported. Segment revenues are used only to explain the top-line mix; consolidated functional expenses provide the downstream bridge and avoid mixing segment measures with GAAP operating income.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| North American Pharmaceutical | 1 | $88.3B | Drug distribution · 83% of revenue |
| Oncology & Multispecialty | 1 | $13.0B | Specialty practices and therapies · +37% |
| Prescription Technology | 1 | $1.5B | Access, affordability and adherence tools |
| Medical-Surgical Solutions | 1 | $3.0B | Supplies for alternate sites of care |
| Other | 1 | $335M | Remaining operations |
| Revenue | 2 | $106.2B | Up 11% year over year |
| Gross profit | 3 | $3.7B | 3.47% gross margin |
| Cost of medicines & products | 3 | $102.5B | 96.5 cents of every revenue dollar |
| Operating income | 4 | $1.6B | 1.53% operating margin |
| Selling, distribution, G&A | 4 | $2.0B | Nationwide logistics and commercial network |
| Restructuring & impairment | 4 | $36M | Portfolio and operating changes |
| Other income | 4 | $74M | Non-operating income |
| Income before tax | 5 | $1.6B | 1.54% of revenue |
| Interest expense | 5 | $63M | Debt financing |
| Net income | 6 | $1.3B | Consolidated result |
| Income tax | 6 | $380M | 23.3% effective rate |
| Net income attributable to McKesson | 7 | $1.2B | $9.59 diluted EPS |
| Noncontrolling interests | 7 | $64M | Practice and business ownership interests |
| From | To | Value |
|---|---|---|
| North American Pharmaceutical | Revenue | $88.3B |
| Oncology & Multispecialty | Revenue | $13.0B |
| Prescription Technology | Revenue | $1.5B |
| Medical-Surgical Solutions | Revenue | $3.0B |
| Other | Revenue | $335M |
| Revenue | Gross profit | $3.7B |
| Revenue | Cost of medicines & products | $102.5B |
| Gross profit | Operating income | $1.6B |
| Gross profit | Selling, distribution, G&A | $2.0B |
| Gross profit | Restructuring & impairment | $36M |
| Operating income | Income before tax | $1.6B |
| Other income | Income before tax | $74M |
| Operating income | Interest expense | $63M |
| Income before tax | Net income | $1.3B |
| Income before tax | Income tax | $380M |
| Net income | Net income attributable to McKesson | $1.2B |
| Net income | Noncontrolling interests | $64M |